Amring Pharma Enters into License and Development Agreement with Amzell for a clinical-stage program
“With the completion of this agreement and the acquisition of broad commercial rights, Amring is rapidly expanding its position as an important leader in bringing critical and affordable treatments for patients...."
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides value-driven brands and niche generics to the market. The company is a subsidiary of SEVER Life Sciences B.V., a global private specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies. Amring is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
About Amzell B.V.
Amzell B.V. is a specialist development pharmaceutical company which takes candidate drugs and devices either through to proof of efficacy or through to marketing authorization for further commercialisation in partnership with leading niche-based commercial healthcare companies. The company, based in Hoofddorp in the Netherlands, was founded in 2016. Amzell has a particular interest in developing well-characterized, active pharmaceutical ingredients utilizing innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance.